SCHEMBL7101972

SCHEMBL7101972

Cc1ccc(C)c([N+](=O)[O-])c1C=O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.54
TDP1 Q9NUW8 4/20 0.54
TSHR P16473 8/20 0.47
CYP3A4 P08684 5/20 0.42
HSD17B10 Q99714 2/20 0.38
RECQL P46063 1/20 0.37
ACHE P22303 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
PDE2A O00408 1/20 0.35
PDE5A O76074 1/20 0.35
ALOX15 P16050 1/20 0.35
NFKB1 P19838 1/20 0.35
APEX1 P27695 1/20 0.35
PDE4A P27815 1/20 0.35
BLM P54132 1/20 0.35
PDE1B Q01064 1/20 0.35
PMP22 Q01453 1/20 0.35
PDE4B Q07343 1/20 0.35
PDE4D Q08499 1/20 0.35
PDE7A Q13946 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23925174 0.85 TSHR (0.49) ALDH1A1TDP1TSHRCYP3A4HSD17B10
SCHEMBL31184578 0.83 TDP1 (0.46) ALDH1A1TDP1TSHRCYP3A4HSD17B10
SCHEMBL4427648 0.79 ALDH1A1 (0.71) ALDH1A1TDP1TSHRCYP3A4HSD17B10
Dioxane SCHEMBL23925107 0.77 TSHR (0.41) ALDH1A1TDP1TSHRCYP3A4RECQL
SCHEMBL23925201 0.77 KMT2A (0.52) ALDH1A1TDP1SMN1; SMN2
SCHEMBL23924915 0.77 ALDH1A1 (0.48) ALDH1A1TDP1TSHRCYP3A4
SCHEMBL29990063 0.77 ALDH1A1 (0.48) ALDH1A1TDP1TSHRCYP3A4
SCHEMBL6959591 0.76 TSHR (0.50) ALDH1A1TDP1TSHRCYP3A4HSD17B10
SCHEMBL28107054 0.76 ALDH1A1 (0.50) ALDH1A1TDP1TSHRCYP3A4HSD17B10
SCHEMBL3420520 0.74 ALDH1A1 (0.43) ALDH1A1TDP1TSHRCYP3A4RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030073850-A1 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use ABBOTT LABORATORIES 2003-04-17 US disclosed
EP-1259491-A1 4-IMIDAZOLE DERIVATIVES OF BENZYL AND RESTRICTED BENZYL SULFONAMIDES, SULFAMIDES, UREAS, CARBAMATES AND AMIDES AND THEIR USE AS ALPHA-1A AGONISTS Abbott Laboratories (US) 2002-11-27 EP disclosed
WO-2001060802-A1 4-IMIDAZOLE DERIVATIVES OF BENZYL AND RESTRICTED BENZYL SULFONAMIDES, SULFAMIDES, UREAS, CARBAMATES, AND AMIDES AND THEIR USE AS ALPHA-1A AGONISTS ABBOTT LABORATORIES (US) 2001-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073850-A1 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use ADRA1D, ADRB1, ADRA1A ALDH1A1 263/4885TDP1 2857/4885TSHR 155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.